Category Archives: Non Small Cell Lung Cancer
First-Line Erlotinib Triples Progression-Free Survival in NSCLC in Chinese Population
First-line erlotinib (Tarceva) tripled the progression-free survival in advanced non–small cell lung carcinoma (NSCLC) patients who had endothelial growth factor receptor (EGFR)-activating mutation, according to the OPTIMAL study presented at the 35th European Society for Medical Oncology Congress. The study … Continue reading
Gefitinib (Iressa) is better than Standard Therapy in Lung Cancer with EGFR Mutations
Gefitinib (Iressa) is more effective than first-line therapy in improving survival without disease in patients with advanced nonsmall-cell lung cancer (NSCLC) and epidermal growth-factor receptor (EGFR) mutations. The current study was conducted in 230 patients from 43 centers in Japan, … Continue reading
Is Shark Cartilage Helpful For Cancer Patients?
Shark cartilage has been touted as a potential alternative or complementary cancer treatment for several decades. Dozens of shark cartilage products are sold as dietary supplements, but none have been studied in humans. A recently published study indicated that adding a … Continue reading
Another Option in the Second Line Treatment of Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Docetaxel(Taxotere) has long been considered the standard of care for second-line treatment of advanced NSCLC. However, the disadvantage of using this agent include the need to administer it with corticosteroid premedication and its toxicity profile A new study published in … Continue reading